Gene Editing with CRISPR-Cas9 Technology for Hepatitis B Virus: A Literature Review
DOI:
https://doi.org/10.35799/jbl.v15i3.65836Keywords:
Hepatitis B, CRISPR-Cas9, cccDNA, Gene EditingAbstract
Hepatitis B Virus (HBV) is a global problem with a significant impact on morbidity and mortality rates that are expected to continue to increase if no further treatment is carried out. HBV is caused by the Hepatitis virus type B, which until now has no medical therapy that can eliminate HBV. The latest developments referring to gene editing for genetic and non-genetic diseases are clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. CRISPR-Cas9 appears with a promising approach with solutions to various disease disorders. CRISPR-Cas9 with DNA editing by Cas9 endonuclease, which is guided by the RNA sequence is able to pair with the target base sequence. The purpose of this paper is to examine the effectiveness and potential of the gene editing method with CRISPR-Cas9 as a therapy for Hepatitis B disease. The writing method is a Literature Review with databases obtained through Google Scholar, PubMed, and ScienceDirect. Various studies and methods have been developed to improve the success of CRISPR-Cas9. Off-target effects are detected to reduce the risk of CRISPR-Cas9. The results show that CRISPR-Cas9 can inhibit HBV replication in vitro and in vivo. Therefore, the technology shows much-needed potential for eradicating the hepatitis B virus. However, further studies are needed to determine its safety and effectiveness as a hepatitis B therapy.
References
Alberts, C. J., Clifford, G. M., Georges, D., Negro, F., Lesi, O. A., Hutin, Y. J.-F., & de Martel, C. (2022). Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. The Lancet Gastroenterology & Hepatology, 7(8), 724–735. https://doi.org/10.1016/S2468-1253(22)00050-4
Aljabali, A. A. A., El-Tanani, M., & Tambuwala, M. M. (2024). Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology, 92, 105338. https://doi.org/10.1016/j.jddst.2024.105338
Ansori, A. NM., Antonius, Y., Susilo, R. JK., Hayaza, S., Kharisma, V. D., Parikesit, A. A., Zainul, R., Jakhmola, V., Saklani, T., Rebezov, M., Ullah, Md. E., Maksimiuk, N., Derkho, M., & Burkov, P. (2023). Application of CRISPR-Cas9 genome editing technology in various fields: A review. Narra J, 3(2), e184. https://doi.org/10.52225/narra.v3i2.184
Asmamaw Mengstie, M., Teshome Azezew, M., Asmamaw Dejenie, T., Teshome, A. A., Tadele Admasu, F., Behaile Teklemariam, A., Tilahun Mulu, A., Mekonnen Agidew, M., Adugna, D. G., Geremew, H., & Abebe, E. C. (2024a). Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. Biologics: Targets and Therapy, Volume 18, 21–28. https://doi.org/10.2147/BTT.S429411
Batra, R., Nelles, D. A., Pirie, E., Blue, S. M., Marina, R. J., Wang, H., Chaim, I. A., Thomas, J. D., Zhang, N., Nguyen, V., Aigner, S., Markmiller, S., Xia, G., Corbett, K. D., Swanson, M. S., & Yeo, G. W. (2017). Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. Cell, 170(5), 899-912.e10. https://doi.org/10.1016/j.cell.2017.07.010
Cai, B., Chang, S., Tian, Y., & Zhen, S. (2023). CRISPR/Cas9 for hepatitis B virus infection treatment. Immunity, Inflammation and Disease, 11(5). https://doi.org/10.1002/iid3.866
Campbell, C., Wang, T., McNaughton, A. L., Barnes, E., & Matthews, P. C. (2021). Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis. Journal of Viral Hepatitis, 28(3), 493–507. https://doi.org/10.1111/jvh.13452
Christian, J. E., Yuliawuri, H., Gunawan, N., & Charlotte, Y. (2024). Uji Diagnostik Virus Hepatitis B dan CRISPR-Cas Sebagai Alternatif: Sebuah Tinjauan Pustaka. Journal of Medicine and Health, 6(1), 103–114. https://doi.org/10.28932/jmh.v6i1.5959
Feng, X., Li, Z., Liu, Y., Chen, D., & Zhou, Z. (2024). CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Experimental Hematology & Oncology, 13(1), 102. https://doi.org/10.1186/s40164-024-00570-y
Gorsuch, C. L., Nemec, P., Yu, M., Xu, S., Han, D., Smith, J., Lape, J., van Buuren, N., Ramirez, R., Muench, R. C., Holdorf, M. M., Feierbach, B., Falls, G., Holt, J., Shoop, W., Sevigny, E., Karriker, F., Brown, R. v., Joshi, A., … Rhoden Smith, A. (2022). Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Molecular Therapy, 30(9), 2909–2922. https://doi.org/10.1016/j.ymthe.2022.05.013
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1143157
He, W., Zheng, Z., Zhao, Q., Zhang, R., & Zheng, H. (2024). Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B. Pathogens, 13(12), 1100. https://doi.org/10.3390/pathogens13121100
Howell, J., Seaman, C., Wallace, J., Xiao, Y., Scott, N., Davies, J., de Santis, T., Adda, D., El-Sayed, M., Feld, J. J., Gane, E., Lacombe, K., Lesi, O., Mohamed, R., Silva, M., Tu, T., Revill, P., & Hellard, M. E. (2023). Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology, 78(3), 976–990. https://doi.org/10.1097/HEP.0000000000000430
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023). Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nature Reviews Gastroenterology & Hepatology, 20(8), 524–537. https://doi.org/10.1038/s41575-023-00760-9
Hu, Z., Zhang, H., Liu, W., Yin, Y., Jiang, J., Yan, C., Wang, Y., & Li, L. (2022). Mechanism of HBV-positive liver cancer cell exosomal miR-142-3p by inducing ferroptosis of M1 macrophages to promote liver cancer progression. Translational Cancer Research, 11(5), 1173–1187. https://doi.org/10.21037/tcr-22-96
Kostyushev, D., Brezgin, S., Kostyusheva, A., Zarifyan, D., Goptar, I., & Chulanov, V. (2019). Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cellular and Molecular Life Sciences, 76(9), 1779–1794. https://doi.org/10.1007/s00018-019-03021-8
Kostyushev, D., Kostyusheva, A., Brezgin, S., Ponomareva, N., Zakirova, N. F., Egorshina, A., Yanvarev, D. v., Bayurova, E., Sudina, A., Goptar, I., Nikiforova, A., Dunaeva, E., Lisitsa, T., Abramov, I., Frolova, A., Lukashev, A., Gordeychuk, I., Zamyatnin, A. A., Ivanov, A., & Chulanov, V. (2023). Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9. Molecular Therapy - Nucleic Acids, 31, 482–493. https://doi.org/10.1016/j.omtn.2023.02.001
Kurniawan, J. (2021). Perkembangan Terapi Hepatitis B Kronis di Indonesia. Jurnal Penyakit Dalam Indonesia, 8(3), 110. https://doi.org/10.7454/jpdi.v8i3.632
Lim, S. G., Baumert, T. F., Boni, C., Gane, E., Levrero, M., Lok, A. S., Maini, M. K., Terrault, N. A., & Zoulim, F. (2023). The scientific basis of combination therapy for chronic hepatitis B functional cure. Nature Reviews Gastroenterology & Hepatology, 20(4), 238–253. https://doi.org/10.1038/s41575-022-00724-5
Lv, W., Li, T., Wang, S., Wang, H., Li, X., Zhang, S., Wang, L., Xu, Y., & Wei, W. (2021). The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer. Technology in Cancer Research & Treatment, 20. https://doi.org/10.1177/15330338211045206
Manghwar, H., Li, B., Ding, X., Hussain, A., Lindsey, K., Zhang, X., & Jin, S. (2020). CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off‐Target Evaluation, and Strategies to Mitigate Off‐Target Effects. Advanced Science, 7(6). https://doi.org/10.1002/advs.201902312
Martinez, M. G., Boyd, A., Combe, E., Testoni, B., & Zoulim, F. (2021). Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. Journal of Hepatology, 75(3), 706–717. https://doi.org/10.1016/j.jhep.2021.05.013
Martinez, M. G., Combe, E., Inchauspe, A., Mangeot, P. E., Delberghe, E., Chapus, F., Neveu, G., Alam, A., Carter, K., Testoni, B., & Zoulim, F. (2022). CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio, 13(2). https://doi.org/10.1128/mbio.02888-21
Murai, K., Kodama, T., Hikita, H., Shimoda, A., Fukuoka, M., Fukutomi, K., Shigeno, S., Shiode, Y., Motooka, D., Higuchi, Y., Miyakawa, K., Suemizu, H., Ryo, A., Tahata, Y., Makino, Y., Yamada, R., Sakamori, R., Tatsumi, T., & Takehara, T. (2022). Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy. Hepatology Communications, 6(9), 2474–2487. https://doi.org/10.1002/hep4.2014
Noor, S., Rasul, A., Iqbal, M. S., Ahmed, B., Akash, M. S. H., & Qadir, M. I. (2020). Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology. Critical Reviews in Eukaryotic Gene Expression, 30(3), 273–278. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020028453
Pausch, P., Al-Shayeb, B., Bisom-Rapp, E., Tsuchida, C. A., Li, Z., Cress, B. F., Knott, G. J., Jacobsen, S. E., Banfield, J. F., & Doudna, J. A. (2020). CRISPR-CasΦ from huge phages is a hypercompact genome editor. Science, 369(6501), 333–337. https://doi.org/10.1126/science.abb1400
Putri, N. A. S., Aswin, R. H., Fithriyah, I., Maimunah, U., Miftahussurur, M., & Yamaoka, Y. (2022). Quality of Life of Chronic Hepatitis B Patients Consuming Nucleoside Analog: A Case-Control Clinical Study in Indonesia. Biomolecular and Health Science Journal, 5(1), 6–10. https://doi.org/10.20473/bhsj.v5i1.31409
Rasheed, A., Gill, R. A., Hassan, M. U., Mahmood, A., Qari, S., Zaman, Q. U., Ilyas, M., Aamer, M., Batool, M., Li, H., & Wu, Z. (2021). A Critical Review: Recent Advancements in the Use of CRISPR/Cas9 Technology to Enhance Crops and Alleviate Global Food Crises. Current Issues in Molecular Biology, 43(3), 1950–1976. https://doi.org/10.3390/cimb43030135
Salpini, R., D’Anna, S., Benedetti, L., Piermatteo, L., Gill, U., Svicher, V., & Kennedy, P. T. F. (2022). Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure. Frontiers in Microbiology, 13. https://doi.org/10.3389/fmicb.2022.972687
Sari, M., & Kasasiah, A. (2024). Tinjauan Literatur Sistematis; Pemanfaatan Teknologi CRISPR-CAS9 Untuk Pengobatan Penyakit Huntington’s. Media Farmasi, 20(2), 151–160. https://doi.org/10.32382/mf.v20i2.704
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M. K., & VandenDriessche, T. (2018). Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9. Molecular Therapy, 26(5), 1241–1254. https://doi.org/10.1016/j.ymthe.2018.02.023
Singh, K., Fronza, R., Evens, H., Chuah, M. K., & VandenDriessche, T. (2024). Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors. Molecular Therapy - Methods & Clinical Development, 32(4), 101365. https://doi.org/10.1016/j.omtm.2024.101365
Smekalova, E. M., Martinez, M. G., Combe, E., Kumar, A., Dejene, S., Leboeuf, D., Chen, C.-Y., Dorkin, J. R., Shuang, L. S., Kieft, S., Young, L., Barrera, L. A., Packer, M. S., Ciaramella, G., Testoni, B., Gregoire, F., & Zoulim, F. (2024). Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo. Molecular Therapy Nucleic Acids, 35(1), 102112. https://doi.org/10.1016/j.omtn.2023.102112
Stone, D., Long, K. R., Loprieno, M. A., de Silva Feelixge, H. S., Kenkel, E. J., Liley, R. M., Rapp, S., Roychoudhury, P., Nguyen, T., Stensland, L., Colón-Thillet, R., Klouser, L. M., Weber, N. D., Le, C., Wagoner, J., Goecker, E. A., Li, A. Z., Eichholz, K., Corey, L., … Jerome, K. R. (2021). CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Molecular Therapy - Methods & Clinical Development, 20, 258–275. https://doi.org/10.1016/j.omtm.2020.11.014
Usmar, U., Nurul Fitri, A. M., Yuliana, D., & Nainu, F. (2021). Review : Imunoterapi Penanganan Infeksi Virus. Jurnal Mandala Pharmacon Indonesia, 7(1), 83–111. https://doi.org/10.35311/jmpi.v7i1.76
Veracruz, N., Gish, R. G., Cheung, R., Chitnis, A. S., & Wong, R. J. (2022). Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019. Journal of Viral Hepatitis, 29(5), 352–365. https://doi.org/10.1111/jvh.13663
Walther, J., Porenta, D., Wilbie, D., Seinen, C., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2024). Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 196, 114207. https://doi.org/10.1016/j.ejpb.2024.114207
Wang, D., Chen, L., Li, C., Long, Q., Yang, Q., Huang, A., & Tang, H. (2022). CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy. Journal of Nanobiotechnology, 20(1), 27. https://doi.org/10.1186/s12951-021-01233-4
Wang, Y., Guo, L., Shi, J., Li, J., Wen, Y., Gu, G., Cui, J., Feng, C., Jiang, M., Fan, Q., Tang, J., Chen, S., Zhang, J., Zheng, X., Pan, M., Li, X., Sun, Y., Zhang, Z., Li, X., … Li, F. (2023). Interferon stimulated immune profile changes in a humanized mouse model of HBV infection. Nature Communications, 14(1), 7393. https://doi.org/10.1038/s41467-023-43078-5
Yan, K., Feng, J., Liu, X., Wang, H., Li, Q., Li, J., Xu, T., Sajid, M., Ullah, H., Zhou, L., Zhou, L., & Chen, Y. (2021). Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters. Frontiers in Microbiology, 12. https://doi.org/10.3389/fmicb.2021.665184
Zeng, W., Zheng, L., Li, Y., Yang, J., Mao, T., Zhang, J., Liu, Y., Ning, J., Zhang, T., Huang, H., Chen, X., & Lu, F. (2024). Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration. Emerging Microbes & Infections, 13(1). https://doi.org/10.1080/22221751.2023.2284286
Zhang, C., Liu, Y., Zhao, H., & Wang, G. (2022). Global Patterns and Trends in Total Burden of Hepatitis B from 1990 to 2019 and Predictions to 2030. Clinical Epidemiology, Volume 14, 1519–1533. https://doi.org/10.2147/CLEP.S389853
Zhang, C., Xu, W., Wang, F., Kang, G., Yuan, S., Lv, X., Li, L., Liu, Y., & Yang, J. (2020). Expanding the base editing scope to GA and relaxed NG PAM sites by improved xC as9 system. Plant Biotechnology Journal, 18(4), 884–886. https://doi.org/10.1111/pbi.13259
Zhuo, C., Zhang, J., Lee, J.-H., Jiao, J., Cheng, D., Liu, L., Kim, H.-W., Tao, Y., & Li, M. (2021). Spatiotemporal control of CRISPR/Cas9 gene editing. Signal Transduction and Targeted Therapy, 6(1), 238. https://doi.org/10.1038/s41392-021-00645-w
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ferencia Rattu
This work is licensed under a Creative Commons Attribution 4.0 International License.
